文献速递真菌感染

新型真菌CYP51抑制剂VT-1598单用及联合脂质体两性霉素B在隐球菌性脑膜炎小鼠模型中有效

The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

在隐球菌性脑膜炎小鼠模型中,口服VT-1598显示良好的血浆和脑暴露,显著且剂量依赖性地降低脑真菌负荷达6 log10,中高剂量使负荷降至治疗前水平以下;生存研究中VT-1598组无动物死亡,停药6天后中高剂量组几乎无再生长(<0.5 log10);亚治疗剂量与脂质体两性霉素B联合均较相应单药有正向效果。

要点

  • VT-1598口服后血浆和脑暴露良好,脑真菌负荷呈剂量依赖性显著下降(P < 0.0001),最大降幅达6 log10。
  • 生存研究中VT-1598组无动物死亡;停药6天后中高剂量组再生长<0.5 log10,而氟康唑组增加2.5 log10。
  • 亚治疗剂量VT-1598与脂质体两性霉素B联合均较相应单药有正向效果。

核心结论

  • 这些临床前体内数据强烈支持将VT-1598作为这一致死性感染的新型疗法进行临床研究。

研究设计与样本

  • 小鼠隐球菌性脑膜炎模型,先测定单剂血浆和脑药代动力学及新型隐球菌H99的MIC,再探索短程单药和联合给药(终点为脑真菌负荷),并开展单药生存研究(停药6天后测真菌负荷)。

主要发现

  • 口服VT-1598血浆和脑暴露良好,脑真菌负荷显著(P < 0.0001)且剂量依赖性降低,达6 log10降幅。
  • 与阳性对照药氟康唑或脂质体两性霉素B不同,VT-1598中、高剂量使真菌负荷降至治疗开始时的水平以下。
  • 生存研究中无VT-1598治疗动物死于感染;停药6天后氟康唑组真菌负荷增加2.5 log10,而VT-1598中、高剂量组几乎无再生长(<0.5 log10)。
  • 在采用亚治疗剂量VT-1598和脂质体两性霉素B探索联合效应的单独真菌负荷研究中,每种联合均较相应单药有正向效果。

关键数值与推荐

  • VT-1598对新型隐球菌H99的MIC及单剂血浆和脑药代动力学参数原文未给出具体数值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Annual global deaths from cryptococcal meningitis (CM) are estimated at 180 000 and mortality is as high as 30%, even with optimal therapy. VT-1598 is a novel fungal CYP51 inhibitor with potent intrinsic antifungal activity against Cryptococcus. We report here VT-1598's in vivo antifungal activity in a murine model of CM. METHODS: Single-dose plasma and brain pharmacokinetics in mice and MIC for Cryptococcus neoformans H99 were determined prior to efficacy studies. Short-course monotherapy and combination doses were explored with the endpoint of brain fungal burden. A survival study was also conducted using monotherapy treatment with fungal burden measured after a 6 day drug washout. RESULTS: Oral doses of VT-1598 had good plasma and brain exposure and resulted in significant (P < 0.0001) and dose-dependent reductions in brain fungal burden, reaching a 6 log10 reduction. Unlike either positive drug control (fluconazole or liposomal amphotericin B), both mid and high doses of VT-1598 reduced fungal burden to below levels measured at the start of treatment. When VT-1598 was dosed in the survival study, no VT-1598-treated animal succumbed to the infection. Whereas fluconazole showed a 2.5 log10 increase in fungal burden after the 6 day washout, the VT-1598 mid- and high-dose animals showed almost no regrowth (<0.5 log10). In a separate fungal burden study using suboptimal doses of VT-1598 and liposomal amphotericin B to probe for combination effects, each combination had a positive effect relative to corresponding monotherapies. CONCLUSIONS: These pre-clinical in vivo data strongly support clinical investigation of VT-1598 as a novel therapy for this lethal infection.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Garvey EP, Sharp AD, Warn PA, et al. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis. J Antimicrob Chemother. 2018. PMID: 29947783. doi:10.1093/jac/dky242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。